NZ535200A - A method of treating diabetes mellitus including conditions associated with diabetes mellitus and complications of diabetes mellitus - Google Patents

A method of treating diabetes mellitus including conditions associated with diabetes mellitus and complications of diabetes mellitus

Info

Publication number
NZ535200A
NZ535200A NZ535200A NZ53520003A NZ535200A NZ 535200 A NZ535200 A NZ 535200A NZ 535200 A NZ535200 A NZ 535200A NZ 53520003 A NZ53520003 A NZ 53520003A NZ 535200 A NZ535200 A NZ 535200A
Authority
NZ
New Zealand
Prior art keywords
phytostanol
insulin
group
phytosterol
derivatives
Prior art date
Application number
NZ535200A
Other languages
English (en)
Inventor
Haydn P Pritchard
Kishor M Wasan
Tatjana Lukic
Original Assignee
Forbes Medi Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forbes Medi Tech Inc filed Critical Forbes Medi Tech Inc
Publication of NZ535200A publication Critical patent/NZ535200A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ535200A 2002-03-14 2003-03-14 A method of treating diabetes mellitus including conditions associated with diabetes mellitus and complications of diabetes mellitus NZ535200A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9874502A 2002-03-14 2002-03-14
PCT/CA2003/000369 WO2003075931A1 (en) 2002-03-14 2003-03-14 A method of treating diabetes mellitus including conditions associated with diabetes mellitus and complications of diabetes mellitus

Publications (1)

Publication Number Publication Date
NZ535200A true NZ535200A (en) 2007-07-27

Family

ID=27804294

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ535200A NZ535200A (en) 2002-03-14 2003-03-14 A method of treating diabetes mellitus including conditions associated with diabetes mellitus and complications of diabetes mellitus

Country Status (11)

Country Link
EP (1) EP1482950A1 (pt)
JP (1) JP2005528353A (pt)
KR (1) KR20040104513A (pt)
CN (1) CN1681514A (pt)
AU (1) AU2003218547B2 (pt)
BR (1) BR0308396A (pt)
CA (1) CA2478931A1 (pt)
NO (1) NO20044346L (pt)
NZ (1) NZ535200A (pt)
RU (1) RU2334518C2 (pt)
WO (1) WO2003075931A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0329667D0 (en) 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
US20080182801A1 (en) 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
GB0513881D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
GB0513883D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Diagnosis of Atherosclerosis
GB0513888D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
HUE035862T2 (en) * 2009-09-28 2018-05-28 Intarcia Therapeutics Inc Rapid development and / or completion of substantially steady-state drug delivery
EP3344071A4 (en) * 2015-09-03 2019-10-16 Natural Shield Israel 2016 Ltd. COMBINED COMPOSITIONS FOR REGULATING GLYCEMIA LEVELS, HEPATOPROTECTION, AND FOR THE PREVENTION AND TREATMENT OF ASSOCIATED MEDICAL CONDITIONS

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1189924B1 (en) * 1999-06-23 2004-08-18 Forbes Medi-Tech Inc. Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease

Also Published As

Publication number Publication date
RU2334518C2 (ru) 2008-09-27
JP2005528353A (ja) 2005-09-22
NO20044346L (no) 2004-12-09
CN1681514A (zh) 2005-10-12
RU2004130463A (ru) 2005-04-10
EP1482950A1 (en) 2004-12-08
BR0308396A (pt) 2005-01-11
KR20040104513A (ko) 2004-12-10
AU2003218547A1 (en) 2003-09-22
WO2003075931A1 (en) 2003-09-18
AU2003218547B2 (en) 2007-11-01
CA2478931A1 (en) 2003-09-18

Similar Documents

Publication Publication Date Title
US6129924A (en) Diglyceride and sterol based organometallic complexes and pharmaceutical compositions and dietetic products containing them
US20020156051A1 (en) Novel structures comprising phytosterol and/or phytostanol and ascorbic acid and use thereof in treating or preventing cardiovascular disease, its underlying conditions and other disorders
US8097635B2 (en) Insulin resistance improving agent
US7645749B2 (en) Sterol/stanol nitroderivatives and use thereof
AU2003218547B2 (en) A method of treating diabetes mellitus including conditions associated with diabetes mellitus and complications of diabetes mellitus
US9642875B2 (en) Compounds and their effects on appetite control and insulin sensitivity
JP2008222656A (ja) 肥満改善および予防用組成物ならびに健康食品
WO2001066560A2 (en) Novel derivatives comprising phytosterols and/or phytostanols and alpha-lipoic and use thereof in treating or preventing cardiovascular disease, its underlying conditions and other disorders
EP1644007B1 (en) Composition comprising one or more phytosterols and/or phytostanols and glucomannan and uses of the composition in treating lipid disorders in individuals with and without type ii diabetes
KR20180075423A (ko) 알룰로스를 포함하는, 식물성 유지의 생체 외 배출 촉진용 조성물
AU2006201562A1 (en) Novel crystalline composites comprising phytosterols and phytostanols or derivatives thereof
EP1333838B1 (en) Compounds comprising a phytosterol and/or phytostanol moiety and ascorbic acid and use thereof as weight regulating agents
KR20080024075A (ko) 신규한 스티그마스테롤 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법, 및 이를 포함하는 비만억제 또는 고지혈증 예방 및 치료용 조성물
US20090312294A1 (en) Method and Agent for Reducing Weight, Accelerating Lipid Catabolism, and/or Restricting Calories
CA2456030A1 (en) Hypoglycemic agent
AU2007203095A1 (en) Compounds comprising a phytosterol and/or phytostanol moiety and ascorbis acid and use thereof as weight regulating agents
CA2461136A1 (en) A method of reducing the in vivo cholesterol ester transfer protein mediated transfer of cholesteryl esters between high density lipoproteins (hdl) and low density lipoproteins (ldl)
AU2002328714A1 (en) A method of reducing the in vivo cholesterol ester transfer protein mediated transfer of cholesteryl esters between high density lipoproteins (HDL) and low density lipoproteins (LDL)

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)